AU2014214020B2 - Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains - Google Patents

Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains Download PDF

Info

Publication number
AU2014214020B2
AU2014214020B2 AU2014214020A AU2014214020A AU2014214020B2 AU 2014214020 B2 AU2014214020 B2 AU 2014214020B2 AU 2014214020 A AU2014214020 A AU 2014214020A AU 2014214020 A AU2014214020 A AU 2014214020A AU 2014214020 B2 AU2014214020 B2 AU 2014214020B2
Authority
AU
Australia
Prior art keywords
cells
cell
compound
amg
glucocorticoidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014214020A
Other languages
English (en)
Other versions
AU2014214020A1 (en
Inventor
Elaine-Pashupati DOPFER
Patrick Hoffmann
Matthias Klinger
Peter Kufer
Virginie Naegele
Dirk Nagorsen
Juergen Scheele
Gerhard Zugmaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of AU2014214020A1 publication Critical patent/AU2014214020A1/en
Application granted granted Critical
Publication of AU2014214020B2 publication Critical patent/AU2014214020B2/en
Priority to AU2019200841A priority Critical patent/AU2019200841B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
AU2014214020A 2013-02-08 2014-02-07 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains Active AU2014214020B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200841A AU2019200841B2 (en) 2013-02-08 2019-02-07 Anti-Leukocyte Adhesion For The Mitigation Of Potential Adverse Events Caused By CD3-Specific Binding Domains

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361762718P 2013-02-08 2013-02-08
US61/762,718 2013-02-08
US201361811526P 2013-04-12 2013-04-12
US61/811,526 2013-04-12
PCT/EP2014/052406 WO2014122251A2 (en) 2013-02-08 2014-02-07 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200841A Division AU2019200841B2 (en) 2013-02-08 2019-02-07 Anti-Leukocyte Adhesion For The Mitigation Of Potential Adverse Events Caused By CD3-Specific Binding Domains

Publications (2)

Publication Number Publication Date
AU2014214020A1 AU2014214020A1 (en) 2015-07-30
AU2014214020B2 true AU2014214020B2 (en) 2018-11-15

Family

ID=50231117

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014214020A Active AU2014214020B2 (en) 2013-02-08 2014-02-07 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
AU2019200841A Active AU2019200841B2 (en) 2013-02-08 2019-02-07 Anti-Leukocyte Adhesion For The Mitigation Of Potential Adverse Events Caused By CD3-Specific Binding Domains

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200841A Active AU2019200841B2 (en) 2013-02-08 2019-02-07 Anti-Leukocyte Adhesion For The Mitigation Of Potential Adverse Events Caused By CD3-Specific Binding Domains

Country Status (12)

Country Link
US (2) US9688760B2 (enExample)
EP (2) EP2953630B1 (enExample)
JP (2) JP6567425B2 (enExample)
AR (1) AR094740A1 (enExample)
AU (2) AU2014214020B2 (enExample)
CA (1) CA2898032C (enExample)
ES (1) ES2811764T3 (enExample)
JO (1) JO3529B1 (enExample)
MX (2) MX2019012421A (enExample)
TW (2) TW201929865A (enExample)
UY (1) UY35313A (enExample)
WO (1) WO2014122251A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2806142T3 (es) * 2011-04-28 2021-02-16 Amgen Res Munich Gmbh Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US10101247B2 (en) * 2013-07-19 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
SI3149480T1 (sl) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN109824778B (zh) * 2015-09-18 2022-07-19 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
US10101248B1 (en) * 2015-12-02 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
JP7015244B2 (ja) 2016-03-22 2022-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ｔ細胞二重特異性分子
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JPWO2018043667A1 (ja) 2016-08-31 2018-08-30 王子ホールディングス株式会社 酸性キシロオリゴ糖の製造方法及び酸性キシロオリゴ糖
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN110678189A (zh) 2017-05-31 2020-01-10 王子控股株式会社 保湿外用剂
EP3683242B1 (en) 2017-09-12 2024-10-30 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
CA3086301C (en) 2017-12-20 2025-04-08 Oji Holdings Corporation PENTOSANNE POLYSULFATE AND MEDICINE CONTAINING PENTOSANNE POLYSULFATE
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020221792A1 (en) * 2019-04-30 2020-11-05 Amgen Research (Munich) Gmbh Means and methods of treating burkitt lymphoma or leukemia
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for generating engineered memory-like nk cells and compositions thereof
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
JP2023517239A (ja) * 2020-03-12 2023-04-24 デイヴィッド カリス－ヒル、シドニー コロナウイルス感染症および関連するサイトカイン毒性の治療
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
AU2021345124A1 (en) * 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4240493A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CN112521513B (zh) * 2020-12-15 2021-08-24 青岛西凯生物技术有限公司 一种靶向cd19的嵌合抗原受体(car)及其应用
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN113637087A (zh) * 2021-07-09 2021-11-12 上海易慕峰生物科技有限公司 一种提高细胞免疫疗法安全性的嵌合受体和细胞
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2024206166A1 (en) * 2023-03-31 2024-10-03 Memorial Sloan-Kettering Cancer Center Microenvironment actuated t-cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010037836A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2012055961A1 (en) * 2010-10-27 2012-05-03 Micromet Gmbh Means and methods for treating dlbcl
WO2012062596A1 (en) * 2010-11-10 2012-05-18 Micromet Gmbh Prevention of adverse effects caused by cd3 specific binding domains

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689848A (en) 1951-02-06 1954-09-21 Wander Ag Dr A Salts of sulfuric acid esters of xylan
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US8007796B2 (en) 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
US20090304657A1 (en) 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
WO2008107906A1 (en) 2007-03-06 2008-09-12 Alembic Limited Process for the preparation of pentosan polysulfate or salts thereof
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2009011893A2 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
EP2178370A4 (en) * 2007-07-17 2011-01-12 Zalicus Inc COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISEASES
CA2733706A1 (en) * 2007-08-10 2009-02-19 Y's Therapeutics Co., Ltd. Modulation of immune responses by administration of roxithromycin or its derivative
US8026343B2 (en) * 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
NZ598732A (en) * 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
ES2806142T3 (es) * 2011-04-28 2021-02-16 Amgen Res Munich Gmbh Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN102875685B (zh) 2012-09-29 2013-12-25 郑骏年 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010037836A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2012055961A1 (en) * 2010-10-27 2012-05-03 Micromet Gmbh Means and methods for treating dlbcl
WO2012062596A1 (en) * 2010-11-10 2012-05-18 Micromet Gmbh Prevention of adverse effects caused by cd3 specific binding domains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAUDHRY IMRAN B ET AL, JOURNAL OF PSYCHOPHARMACOLOGY,vol. 26, no. 9, I (2012-09-01), pages 1185 - 1193, (2012-04-23) *
K. EGUCHI ET AL, "Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells", CLINICAL & EXPERIMENTAL IMMUNOLOGY, (1992-06-01), vol. 88, no. 3, pages 448 - 454 *
SZIRMAI I ET AL, FOLIA HAEMATOLOGICA (LEIPZIG, GERMANY : 1928) 1986, vol. 113, no. 1-2, pages 278 - 288Google Translate used for English Translation *

Also Published As

Publication number Publication date
AU2014214020A1 (en) 2015-07-30
JP6567425B2 (ja) 2019-08-28
EP3760210A1 (en) 2021-01-06
AR094740A1 (es) 2015-08-26
US9688760B2 (en) 2017-06-27
MX2015009922A (es) 2015-09-25
EP2953630B1 (en) 2020-07-01
JP2016514090A (ja) 2016-05-19
TW201442714A (zh) 2014-11-16
AU2019200841A1 (en) 2019-02-28
JP2019178142A (ja) 2019-10-17
WO2014122251A2 (en) 2014-08-14
JO3529B1 (ar) 2020-07-05
JP6933684B2 (ja) 2021-09-08
MX2019012421A (es) 2022-10-13
TW201929865A (zh) 2019-08-01
US20140227272A1 (en) 2014-08-14
MX368842B (es) 2019-10-18
CA2898032C (en) 2021-06-15
US20170327581A1 (en) 2017-11-16
UY35313A (es) 2014-08-29
TWI704920B (zh) 2020-09-21
WO2014122251A3 (en) 2014-10-02
CA2898032A1 (en) 2014-08-14
US11084876B2 (en) 2021-08-10
AU2019200841B2 (en) 2020-08-13
ES2811764T3 (es) 2021-03-15
HK1216996A1 (zh) 2016-12-16
EP2953630A2 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
AU2019200841B2 (en) Anti-Leukocyte Adhesion For The Mitigation Of Potential Adverse Events Caused By CD3-Specific Binding Domains
US20240002515A1 (en) Methods and antibodies for modulation of immunoresponse
CN109589336B (zh) 用于t细胞免疫疗法的组合及其用途
JP2019517773A (ja) 抗ｌａｇ−３抗体
US20190367607A1 (en) Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
JP2016534090A (ja) Ｃｄ３８アゴニストの医学的使用
AU2011215750A1 (en) Therapeutic methods using an ti-CD200 antibodies
US20190292264A1 (en) Klrg1 signaling therapy
US20230125234A1 (en) Anti cd44-ctla4 bispecific antibodies
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
Koenderman et al. Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils
Orden et al. Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150, 95
Kitani et al. T cells bound by vascular cell adhesion molecule-1/CD106 in synovial fluid in rheumatoid arthritis: inhibitory role of soluble vascular cell adhesion molecule-1 in T cell activation
US8858944B2 (en) Treatment drug for autoimmune diseases and allergic diseases
US11079381B2 (en) Risk-stratification of B-precursor acute lymphoblastic leukemia patients
Zugmaier Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
Zekarias Characterization of rituximab-induced B cell depletion and infusion reactions in a human blood loop system
Koenderman et al. Granulocyte-macrophage colony-stimulating factor induces

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)